Monte Rosa Therapeutics, Inc. (GLUE): Price and Financial Metrics
GLUE Price/Volume Stats
| Current price | $8.36 | 52-week high | $12.40 |
| Prev. close | $8.31 | 52-week low | $2.91 |
| Day low | $8.05 | Volume | 736,400 |
| Day high | $8.62 | Avg. volume | 760,506 |
| 50-day MA | $6.66 | Dividend yield | N/A |
| 200-day MA | $5.61 | Market Cap | 513.61M |
GLUE Stock Price Chart Interactive Chart >
Monte Rosa Therapeutics, Inc. (GLUE) Company Bio
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is based in Boston, Massachusetts.
GLUE Price Returns
| 1-mo | 57.44% |
| 3-mo | 32.07% |
| 6-mo | 100.96% |
| 1-year | 180.54% |
| 3-year | -57.41% |
| 5-year | N/A |
| YTD | 47.96% |
| 2023 | -25.76% |
| 2022 | -62.73% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...